Boehncke W,Schön M. .2015 .Disease burden and epidemiology. Lancet, 386 : 983-94.
Abdulridha SH,Kadhim DJ,Razzak SAA .2021 .Beliefs about Medicines among a Sample of Iraqi patients with Psoriasis. Innov Pharm, 12(1) : 3584.
Flytström I. . .Different aspects of psoriasis etiology and treatment. 2012 May, 14 : .
Afra T,Razmi TM,Dogra S. .2019 .Apremilast in psoriasis and beyond: big hopes on a small molecule. Indian Dermatol Online J, 10(1) : 1.
Milakovic M,Gooderham MJ M .2021 .Phosphodiesterase-4 inhibition in psoriasis. Psoriasis: Targets and Therapy, : 21-9.
Gao JC,Wu AG,Contento MN,Maher JM,Cline A .2022 .Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis. Clin Cosm Investig Dermatol, : 395-402.
Yost J,Gudjonsson JE . .The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. 2009;1., : .
Kane D .2004 .Tumor necrosis factor-α in psoriasis and psoriatic arthritis: A clinical, genetic, and histopathologic perspective. Curr Rheumatol Rep, 6(4) : 292-8.
Iyer SS .2012 .Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol, 32(1) : 23-63.
Abdulridha SH,Kadhim DJ,Razzak SAA .2020 .Assessment of Quality of Life in a Sample of Iraqi Patients with Psoriasis. Iraqi J Pharm Sci, 29(2) : 161-8.
.2011 .Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol, 25(9) : 1007-11.
.2018 .Statistical Analysis System, User's Guide. Statistical. Version 9.6. SAS Inst Inc Cary NC USA, : .
Mavropoulos A,Zafiriou E,Simopoulou T,Brotis AG,Liaskos C,Roussaki-Schulze A .2019 .Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis. Rheumatol, 58(12) : 2240-50.
Schafer PH,Chen P,Fang L,Wang A,Chopra R. .2015 .The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res, : .
Gialouri CG,Evangelatos G,Fragoulis GE,or JAK GE .2022 .Inhibitors?. Mediterranean J Rheumatol, 33(Suppl 1) : 150.
Armstrong AW,Puig L,Joshi A,Skup M,Williams D,Li J .2020 .Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol, 156(3) : 258-69.
Sbidian E,Chaimani A,Garcia-Doval I,Doney L,Dressler C,Hua C .2022 .Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. Cochrane Database Syst Rev, 5(5) : CD011535.
Ferguson LD,Cathcart S,Rimmer D,Semple G,Brooksbank K,Paterson C .2022 .Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study. Rheumatol, 61(3) : 1026-34.
Iskandar I,Parisi R,Griffiths C,Ashcroft D,Atlas GP .2021 .Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. Br J Dermatol, 184(2) : 243-58.
Tollefson MM,Crowson CS,McEvoy MT,Kremers HM .2010 .Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol, 62(6) : 979-87.